歌禮制藥-B(01672.HK):利托那韋片完成浙江省首單銷售
格隆匯4月4日丨歌禮制藥-B(01672.HK)發佈公吿,2022年4月3日,歌禮經銷商浙江英特藥業有限責任公司助力歌禮利托那韋片完成浙江省首單銷售。浙江英特為浙江省醫藥流通重點企業。
歌禮為中國抗病毒領先企業,擁有目前中國唯一通過生物等效性研究獲批上市的利托那韋片。歌禮利托那韋片於2021年9月獲中國國家藥品監督管理局批准上市(藥品批准文號:國藥準字H20213698)。
利托那韋片是多種針對病毒蛋白酶的口服抗病毒藥物的藥代動力學增強劑。2022 年3月15日,中國國家衞生健康委員會發布《新型冠狀病毒肺炎診療方案(試行第九版)》,將PF-07321332╱利托那韋片(Paxlovid)納入診療方案。歌禮利托那韋片年產能已擴大至約5.3億片,以保障供應。歌禮已向12個歐洲國家(德國、法國、愛爾蘭、英國、西班牙、葡萄牙、意大利、比利時、波蘭、瑞典、荷蘭和丹麥)及中國香港遞交了利托那韋(100毫克薄膜衣片)上市許可申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.